Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  -3.00p -7.79% 35.50p 65,355 09:01:59
Bid Price Offer Price High Price Low Price Open Price
34.00p 37.00p 38.50p 35.50p 38.50p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.6 -0.2 -4.3 - 1.97

Aortech (AOR) Latest News

More Aortech News
Aortech Takeover Rumours

Aortech (AOR) Share Charts

1 Year Aortech Chart

1 Year Aortech Chart

1 Month Aortech Chart

1 Month Aortech Chart

Intraday Aortech Chart

Intraday Aortech Chart

Aortech (AOR) Discussions and Chat

Aortech Forums and Chat

Date Time Title Posts
23/5/201813:25Aortech - Interesting Biomaterials Business. Market Cap All Cash4,520
19/1/200716:00Aortech with Charts & News6
07/4/200617:46Wakey Wakey! - Aortec in bid talks......70
05/11/200311:47Aortech is an obvious 2-bagger68

Add a New Thread

Aortech (AOR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Aortech trades in real-time

Aortech (AOR) Top Chat Posts

Aortech Daily Update: Aortech International is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker AOR. The last closing price for Aortech was 38.50p.
Aortech International has a 4 week average price of 30.50p and a 12 week average price of 30.50p.
The 1 year high share price is 69.50p while the 1 year low share price is currently 10.50p.
There are currently 5,557,695 shares in issue and the average daily traded volume is 76,715 shares. The market capitalisation of Aortech International is £1,972,981.73.
parsons4: Well the moral of this story is that the price is very rarely WRONG there is always a reason. However they are obviously going for the big time by developing the new products using their IP. If they get it right then it is definitely a ten-bagger in the making. I will take up my open offer shares. I suspect that the share price will not stay near the placing price for long if at all, as there are not many short-termers here IMHO. BUT it is now a much longer term investment !! GLA
the stigologist: #AOR AorTech hTtps:// share price : 44p shares o/s : 5.6m mkt cap : £2.4m balance sheet cash : $0.5m? (Dec 2017 RNS : $328k as of Nov 2017) annual cashflow : c.$0.2m? (H1 Interims : Net Cash from Op. $172k) high quality cashflow from IPR licensing/royalty business model optionality from potential licensing of breast implant/heart valve biocompatible materials potential for use of company as a RTO/shell vehicle ? "The tax losses within the accounts also makes AOR attractive to a prospective buyer, as with millions to play with this could well prove to tempting to a profit making organisation" "£23M will attract deal makers. @20% that's £4.6M Discount that by 50% TAX LOSS IS WORTH MORE THAN TODAYS MARKET CAP" chart looks like it's breaking out (note last breakout above 50 day MA in November 2017 preceded big December 2017 150%+ move) Limited shares in issue, very tightly held
the stigologist: I've worked in listed companies. Listed Investment Management companies to boot. You'd think employees in those sort of firms with heavy equity-linked remuneration and incentivisation would be obsessed by the share price? They're not. They get on with their day to day jobs and let the share price take care of itself. To use BB 'discourse' as some sort of metric to judge the fundamentals of a business is very very small time and idiotic behaviour.
harrogate: Its a while since I have been in to see how things are through the looking glass of the alternative reality world of this board. I see things are little different with Stig here building a story around various pieces of information - of course that is what investment is about and good luck to him but please don't follow the hype. Surely it is clear here that the core material licensing business that was passed to Biomerics while valuable is not going to suddenly take off and as it was said in an RNS some AOR royalties from this arrangement have been taken upfront to pay AOR share of the additional costs in getting the manufacturing processes sorted at Biomerics - we don't know what that might be but it could mean that any new licence revenue doesn't flow to AOR for a good while. The hope here is all about the heartvalve - that is where the home run could be but do we really believe that our management can develop this? They will need significant money and a fundraise must be on the cards here and then it becomes a matter of the dilution and the partners they work with that must be announced at the same time. I am a very long term holder and while it is great that we have settled the court case and are not going bust we are a very long way from creating value beyond the current share price.
mikeh30: """""The long-running litigation dispute created a number of uncertainties for AorTech and its shareholders and at the time of announcing results for the year to 31 March 2017 the share price was implying that AorTech was likely to fail.""""""
bones: Well, there have been discussions in past RNS's about raising the necessary finance (from potential partners rather than AOR) to progress the trialling of AOR's work on the polymer heart valve. I have always gained the impression that AOR have an eye on more than just licensing in this field.Given the recent clearing up of legal disputes over the ex-CEO and his involvement with the heart valves IP, it still leaves questions hanging so we do need to hear what they have in mind in these strategic plans.Does the new NOMAD, Stockdale Securities, have an input here into ways of financing such developments? Will Biomerics be involved?Whatever the case, it should be a catalyst for share price movement.
the stigologist: These are another set of notes I wrote after previous RNSes. Just FYI FWIW for any newbies getting up to speed. So the basics on this are that they developed this Elast-eon technology about 17 years ago. Failed to become a device manufacturer themselves. Licensed the materials tech unsuccessfully initially and on bad terms to much bigger players. Got into loads of litigation to try to protect their Intellectual Property etc. Finally seem to have drawn a line under previous litigation and found a licensing partner Biomerics who is delivering. Reckon that having learnt from previous experiences they can licence their tech successfully for some other devices e.g. Breast implants and Heart Valves. Their current valuation is totally out of sync with what even Private Start-ups are valued at (e.g. Edwards buying Harpoon a couple of weeks ago for $100-250m) which don't have the track record of successful clinical use or FDA approvals. AOR AorTech Share Price : 50p Market Cap : £2.8m AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k's, CE Marks, Australian TGA and Japanese Ministry of Health approvals. Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available. Valuation comparitors :- Major licensee is Biomerics. Private Company. Recently spent $38m on a HQ building alone. hTtp:// Edwards Lifesciences bought Harpoon Medical for $100-250m (December 6th 2017) hxxp:// "The HARPOON system is designed to facilitate echo-guided repair of mitral valve regurgitation, by stabilizing the prolapsed mitral valve leaflet to restore proper coaptation and valve function" Xeltis achieved largest private equity funding round for a medical device in Europe of $52m in 2017 (November 15th 2017) hTtp:// AorTech comments :- General licenses :- "Significant funding has been achieved by AorTech licencees in developing and commercialising their products with AorTech's Elast-Eon™ seen as critical to their success. In one instance, funds in excess of $100 million have been raised to achieve successful commercialisation." On their Heart Valve Project :- "We have previously announced a potential transaction with a new business established to commercialise the AorTech heart valve technology. Fund raising for the new project is continuing but is not yet finalised and any license will be dependent upon the new business being fully funded. The package of data and information that AorTech is able to deliver to the project is substantial. This ranges from specific manufacturing know how and trade secrets for the precise polymer best suited to a heart valve, detailed design files for a polymer valve with a stress/strain profile substantially less than the material mechanical properties, together with a fully documented manufacturing process that allows a clinical quality valve to be made on a repeatable basis. All of these processes have been developed over a number of years of trial and error and experimentation at considerable investment by AorTech."
mikeh30: The results for the year to 31 March 2017 the share price was implying that AorTech was likely to fail.The recent trading results should indicate to shareholders that the business is on a more stable footing and the risk of failure diminished. The cash position improved during the six months to 30 September 2017 and at the end of November 2017 had further increased to $328,000. We anticipate that the net cash position should improve further.A detailed strategic plan to allow AorTech to commercialise its platform technology is currently being considered and we will report to shareholders when the process is concluded
stephen2010: As I posted yesterday evening. Check out ALBA. Huge multibag potential. ALBA currently trading at 0.39p target price 6p making a nice 15 bagger. Please read the following: MARKET CAP PUZZLE ❖ Alba (market cap £8.4m) is in a resources neighbourhood populated with listed companies with much enhanced market capitalisations, such as UKOG.L (£134m) and JAY.L (£172m). With either shared project interests or adjacent tenements to these companies, Alba should trade at a much higher valuation than its current token value. Like Bluejay, Alba owns 100% of its ilmenite project. Direct comparisons with UKOG are also instructive. While both companies own other projects, UKOG’s 49.9% of Horse Hill Developments Limited (HHDL), when compared to Alba’s 18.1% means that Alba has approximately one third of the value of Horse Hill compared to UKOG but only about 7% of the market capitalisation. Once the market recognises these disparities, the room for growth in Alba’s share price is undeniable. VALUATION RATIONALE - Our valuation in this First Equity Limited initiation note uses a risked valuation approach for Alba’s two main projects, at Horse Hill and TBS. The Horse Hill licences are valued using independent published technical data from Schlumberger, Xodus and Nutech on the oil potential of the licences, along with our own assumptions on recovery rates, oil discovery value, resource and development risks factors. From this a risked value of $127m net to Alba on a ‘Base Case’ basis is derived for Horse Hill. Given the similar geology and economic potential of both TBS and Dundas, we have adopted a risked closeology valuation approach, by computing an NPV for Dundas of $223m and then applying a three-tiered risked probability calculation to arrive at a value of $54.7m for TBS. Once Alba announce its JORC resource and exploration target at TBS and Bluejay its Feasibility Study results, this number is likely to be revised upwards very rapidly, possibly up to $200m, representing up to 7p per share in additional shareholder value. We compute a valuation of $185m (£139m) for Alba, equating to 6.0p per share, of which 4.1p is attributed to the stake in Horse Hill, 1.8p for TBS. Given this analysis and wealth of valuation catalysts anticipated across the project portfolio in the coming months, we recommend the shares as a ‘BUY, with a Target Price of 6.0p, representing a potential 15 times plus uplift from the current share price.
only winners please: Look at this companies valuation of £2M , then deduct the cash, cash due, and then add on some on for the settlement. In effect your getting the company for about one million pounds. That’s very very cheap. The recurring revenues are worth about 40 times on a pe basis. If Turnover can grow fast then your looking at a 40 times rise in the share price. Take absolutely no notice of the share price it’s the market cap that counts. Just 5.5 million shares in issue.
Aortech share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20180523 13:10:17